Roche gets NICE approval for advanced bladder cancer
pharmafile | May 17, 2018 | News story | Sales and Marketing | Roche, biotech, drugs, pharma, pharmaceutical, tecentriq
Though trial results for Tecentriq (atezolizumab) may not necessarily be going Roche’s way, after a combination treatment failure, the treatment is still gaining ground with regulators for its initial treatment focus in bladder cancer.
NICE has announced that the immunotherapy will be made available for patients with advanced bladder cancer as a second-line treatment.
The approval does come with conditions: namely, that it can only be provided for two years of treatment or can be halted early if the disease progresses whilst the patient is being treatment.
As is usually the case, NICE has given the nod to the treatment only after it agreed a confidential discount on the list price of the drug, which doesn’t come cheap at the official cost of £3,807.69 per 1,200 mg vial.
Simon Eayrs, Cancer Immunotherapy Franchise Lead at Roche Products UK, commented, “We welcome the news that more bladder cancer patients will now be able to access atezolizumab via the NHS. Atezolizumab has received three out of three positive NICE recommendations, one of these within the Cancer Drugs Fund. We at Roche believe this demonstrates the importance of working collaboratively and flexibly with NICE and NHS England. We’re incredibly proud that patients are able to access the medicines we’ve worked so hard to develop.”
The other two recommendations Roche has received are in second-line use in non-small cell lung cancer and in metastatic bladder cancer –funded by the CDF.
Though Eayrs highlighted the three out of three recommendations by NICE, it was by no means an easy journey to arrive at each approval. In lung cancer the treatment was actually rejected twice before finally receiving the thumbs up from NICE.
The decision will be welcomed by Roche given that sales of Tecentriq have stalled on the back of some shaky data emerging from trials and strength of competitors, particularly MSD’s Keytruda.
Roche announced that sales of the drug were $141 million in the first quarter of 2018, not a huge increase on sales of $115 in the fourth quarter of 2017 and completely dwarfed by the $1.3 billion brought in by Keytruda in Q1.
Ben Hargreaves
Related Content
Pharma sees climate disruption as growing supply-chain risk
Nine in ten pharmaceutical companies across the UK and G7 countries expect climate-related disruption to …
AI in pharma: From lab development to patient impact
In the decade to 2025, AI use in vaccine development has increased markedly but is …
Roche secures CE Mark for automated latent tuberculosis blood test
Roche has received CE Mark approval for its Elecsys IGRA TB test, an automated blood …
